Device Authority targets a more practical route into automotive cybersecurity spending

Tern plc

Device Authority is trying to make its Industry Proof of Value relevant at a point when automotive cybersecurity is becoming a more immediate operational issue for manufacturers and suppliers. The company’s argument is straightforward. PKI and key management are no longer just technical matters. As vehicle architectures become more software-defined and connected, and as regulatory requirements tighten, control over cryptographic processes is moving closer to the centre of how OEMs manage risk, compliance and production.

Device Authority is offering a defined way for OEMs and Tier 1 suppliers to test how secure device identity, certificate lifecycle management, key generation, storage, distribution and BYOK models would work in practice. The point of the PoV is to move discussions away from theory and into a measurable operating model without requiring a full deployment at the outset.

This makes the proposition easier to understand commercially. In markets where decision cycles are long and implementation risk is closely scrutinised, a structured proof environment can help customers test both technical fit and regulatory relevance before making a wider commitment. That is important because buyers in this area are not simply looking for another cybersecurity product. They are trying to establish whether they can show control, retain visibility and support production at scale under tighter compliance expectations.

Device Authority is also placing clear emphasis on regulatory alignment. The source says the PoV is designed to map technical outcomes to requirements such as cryptographic governance, certificate traceability, secure lifecycle controls, production auditability and rapid revocation and update capabilities.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

What HCPs say could reveal prescribing intent

Talking Medicines is using AI to analyse HCP conversations and identify the clinical and practical factors that may influence prescribing intent.

AI control of machines raises new security questions

AI is gaining the ability to control physical equipment, but establishing that machines are genuine, authorised and secure will be an important part of making this technology safe to deploy.

CAR-T therapy brings new approach to multiple myeloma treatment

CAR-T therapy is being used in multiple myeloma and is being studied earlier in the treatment pathway, with research focused on improving durability, safety and access.

Tern cuts H1 loss by 60% as portfolio growth and funding strengthen

Tern reduced its first-half loss by 60%, with net asset value improving and further fundraising strengthening the balance sheet. Additional funding has supported Talking Medicines and Device Authority, while continued progress across the portfolio provides further scope for value creation.

AI control of machines creates a new market for device trust

AI is beginning to control physical machines, increasing demand for technology that can verify device identity before those machines are allowed to act.

Peptide drug development expands beyond GLP-1

GLP-1 success is widening interest in peptide drug development, with the next phase focused on proving clinical value across new therapeutic areas.

Search